Trial Profile
A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism (HI)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jun 2020
Price :
$35
*
At a glance
- Drugs RZ 358 (Primary)
- Indications Hyperinsulinaemia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors XOMA
- 01 Jun 2020 Results published in Rezolute Media Release
- 01 Jun 2020 According to a Rezolute media release, results from this trial were present at the Pediatric Endocrine Society (PES) 2020 Annual Meeting, held virtually.
- 28 May 2020 According to an Rezolute media release, data from single dose studies of RZ358 in patients with Congenital Hyperinsulinism will be presented at Virtual Pediatric Endocrine Society 2020 Annual Meeting.